EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of the mGlu 2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset

Woojin Kang, Imane Frouni, Cynthia Kwan, Dominique Bédard, Stephen G Nuara, Adjia Hamadjida iD, Jim C Gourdon, Philippe Huot iD

European Journal of Neuroscience · 2024

DOI: 10.1111/ejn.16454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Woojin Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada. Hauptthemen laut MEDLINE: Callithrix, Levodopa, Receptors, Metabotropic Glutamate, Antiparkinson Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research, Parkinson Canada, Fonds de Recherche du Québec - Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of metabotropic glutamate 2 (mGlu 2 ) receptors is a potential novel therapeutic approach for the treatment of parkinsonism. Thus, when administered as monotherapy or as adjunct to a low dose of L‐3,4‐dihydroxyphenylalanine (L‐DOPA), the mGlu 2 positive allosteric modulator (PAM) LY‐487,379 alleviated parkinsonism in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned primates. Here, we sought to investigate the effect of biphenyl‐indanone A (BINA), a highly selective mGlu 2 PAM whose chemical scaffold is unrelated to LY‐487,379, to determine if a structurally different mGlu 2 PAM would also confer anti‐parkinsonian benefit. In monotherapy experiments, MPTP‐lesioned marmosets were injected with either vehicle, L‐DOPA/benserazide (15/3.75 mg/kg, positive control) or BINA (0.1, 1, 10 mg/kg). In adjunct to a low L‐DOPA dose experiments, MPTP‐lesioned marmosets were injected with L‐DOPA/benserazide (7.5/1.875 mg/kg) in combination with vehicle or BINA (0.1, 1, 10 mg/kg). Parkinsonism, dyskinesia and psychosis‐like behaviours (PLBs) were then quantified. When administered alone, BINA 1 and 10 mg/kg decreased parkinsonism severity by ~22% ( p < 0.01) and ~47% ( p < 0.001), when compared with vehicle, which was comparable with the global effect of a high L‐DOPA dose. When administered in combination with a low L‐DOPA dose, BINA 1 and 10 mg/kg decreased global parkinsonism by ~38% ( p < 0.001) and ~53% ( p < 0.001). BINA 10 mg/kg decreased global dyskinesia by ~94% ( p < 0.01) and global PLBs by ~92% ( p < 0.01). Our results provide additional evidence that mGlu 2 positive allosteric modulation elicits anti‐parkinsonian effects. That this benefit is not related to a particular chemical scaffold suggests that it may be a class effect rather than the effect of a specific molecule.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CallithrixLevodopaReceptors, Metabotropic GlutamateAntiparkinson AgentsAnimalsMaleFemaleBenserazideParkinsonian DisordersAllosteric RegulationDrug Therapy, CombinationIndansMPTP Poisoning

Stichwörter der Autor:innen

BINAMPTP‐lesioned marmosetPAMParkinsonismdyskinesiamGlu2 receptorpsychosis‐like behaviours

Substanzen

Levodopametabotropic glutamate receptor 2Receptors, Metabotropic GlutamateAntiparkinson AgentsBenserazideIndans

Autor:innen und Institutionen

  • Neurodegenerative Disorders Research Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, Canada.
  • Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada.
  • Comparative Medicine & Animal Resource Centre, McGill University, Montreal, QC, Canada.
  • Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
  • Department of Neurosciences, McGill University Health Centre, Montreal, QC, Canada.

ORCID-Profile: Adjia Hamadjida, Philippe Huot

Förderung

  • Michael J. Fox Foundation for Parkinson's Research
  • Parkinson Canada
  • Fonds de Recherche du Québec - Santé
  • Weston Brain Institute
  • Natural Sciences and Engineering Research Council of Canada
  • New Frontiers in Research Fund
  • CIHR
  • Healthy Brains for Healthy Lives

Zitieren

APA

Kang, W., Frouni, I., Kwan, C., Bédard, D., Nuara, S. G., Hamadjida, A., Gourdon, J. C., & Huot, P. (2024). Effect of the mGlu 2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16454

Vancouver

Kang W, Frouni I, Kwan C, Bédard D, Nuara SG, Hamadjida A, et al. Effect of the mGlu 2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16454

BibTeX
@article{Kang2024,
  author = {Kang, Woojin and Frouni, Imane and Kwan, Cynthia and Bédard, Dominique and Nuara, Stephen G and Hamadjida, Adjia and Gourdon, Jim C and Huot, Philippe},
  title = {Effect of the mGlu 2 positive allosteric modulator biphenyl‐indanone A as a monotherapy and as adjunct to a low dose of L‐DOPA in the MPTP‐lesioned marmoset},
  journal = {European Journal of Neuroscience},
  year = {2024},
  doi = {10.1111/ejn.16454}
}
Kostenlos starten →